Clinical trials: Carfilzomib

Multiple Myeloma

Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

• Withdrawn
• Age: 18 years and older
• Phase 2
• Pill or oral medicine
• Injection or infusion

The purpose of this study is to investigate the anti-myeloma effect of panobinostat given at two different doses (10 mg and 20 mg oral) in combination with carfilzomib (20/56 mg/m2 i.v.) and low dose dexamethasone (20 mg oral) vs…

Trial name

PANORAMA-5 (NCT02756663)

Testing

panobinostat (capsules), carfilzomib (infusion), dexamethasone (tablets)

Sponsor

Novartis Pharmaceuticals